All posts by imreal

Concussions and college students—When is it safe to return to the classroom?


Concussions aren’t limited to celebrity athletes playing high-impact sports. Concussions among college students happen on and off the playing field. Recent research shows a higher incident of concussions in the non-athlete student population and among women students.

The return of college students to the classroom after a concussion is an understudied area that RIT researcher Zachary Bevilacqua hopes to improve.

Because academic rigor can delay recovery students with concussions need to minimize cognitive activity to let their brain heal. Head injuries in young adults can carry serious implications, especially since brain development continues until the mid-twenties. But college students are autonomous and busy with school, athletics or clubs, and many have jobs, and stopping everything for concussion recovery may not be a priority or a possibility for them, even if academic studies provoke symptoms.

Bevilacqua’s research builds on the standardized “Return to Play” guidelines, published by the international Concussion in Sport Group, and protocols for college students returning to the classroom post-concussion. Through a collaboration with athletic trainers in RIT Athletics, Bevilacqua is exploring the prognostic use of oculomotor testing to assess a concussed student’s readiness to return to academics. Oculomotor testing assesses the proper functioning of certain cranial nerves.

“My work will provide an objective underpinning to which guidelines we should keep or revise,” said Bevilacqua, visiting professor of exercise science in RIT’s Wegmans School of Health and Nutrition. “Oculomotor testing assesses an individual’s ability to maintain a clear field of vision while the eyes are in motion, and rapidly process visual information to produce the correct outcome, such as reciting numbers or letters.”

These tests make prognosticating classroom readiness possible because tasks within the classroom use these same cranial nerves to read, process letters and numbers, and for looking back and forth from one’s notes to the professor in front of the class. Bevilacqua is also tracking several variables within each participant in his study that could influence their recovery. These potential confounding variables would otherwise dilute predictive qualities of these tests, he said.

Bevilacqua’s ongoing study complements his previous work, which addresses student behaviors associated with symptom resolution, the influence of educators’ perspectives on academic accommodations, and effective medical-academic communication through medical notes.

“Because a concussion is a brain injury, it’s quite important that students are guided properly,” Bevilacqua said.

To talk to Zachary Bevilacqua about his research, contact Susan Gawlowicz, Senior Communications Specialist at RIT University Communications, at susan.gawlowicz@rit.edu.

Share article on social media or email:

New Legal Aid Eviction and Foreclosure Prevention Program Offers Relief for Renters and Homeowners


OMC is a non-profit, volunteer-based organization that assists Oakland County resident in resolving disputes in a peaceful and respectful manner through mediation and education.

OMC is a non-profit, volunteer-based organization that assists Oakland County resident in resolving disputes in a peaceful and respectful manner through mediation and education.

Our goal is to keep people in their homes and provide support and resources to residents who would normally not receive them — people whose lives have been affected because of COVID-19’s impact.

Oakland Mediation Center (OMC) announces a new Legal Aid Eviction and Foreclosure Prevention program to help renters and property owners, who may have fallen behind on their payments due to COVID-19 pandemic. The services are free for people who qualify.

The program, which launched February 1, 2022, is part of a joint partnership with Lakeshore Legal Aid and Legal Aid and Defenders Association. Awarded by a county grant, the program helps to provide legal assistance to tenants or homeowners at risk of or subject to eviction or foreclosure. OMC’s legal services department has already assisted 166 individuals in addition to the 989 cases facilitated by mediation services in pretrial hearings. Most cases have been resolved within 30 days.

The benefits of the Legal Aid Eviction and Foreclosure Prevention program include access to justice, legal resources, and education that empowers clients. The program also helps relieve the burden and stress related to the eviction process.

“The pandemic has created so many challenges for people who live in Michigan,” said Charity Burke, Executive Director of OMC. “Our goal is to keep people in their homes and provide support and resources to residents who would normally not receive them — people whose lives have been affected because of COVID-19’s impact.”

The Legal Aid Eviction and Foreclosure Prevention program is part of a larger program at OMC offering low-cost legal services. For those who do not qualify for free services, rates range from $60 to $145 per hour depending on income, household size, and the complexity of the case. The average cost for most cases is $120 per hour.

To schedule an appointment, renters and homeowners in Michigan must call 248-338-4280 or email legalservices@mediation-omc.org. Requests can also be submitted through the OMC website.

OMC has partnered with 51st Waterford District Court, 52-4th Troy District Court, 52-3rd Rochester Hills District Court, 48th Bloomfield Hills District Court, and Oakland County to execute the Legal Aid Eviction and Foreclosure Prevention program.

About Oakland Mediation Center: OMC is a non-profit, volunteer-based organization that assists Oakland County resident in resolving disputes in a peaceful and respectful manner through mediation and education. Formed in 1989 at the recommendation of the Oakland County Bar Association, OMC was established to provide individuals with an alternative to the litigation process. For additional information about OMC and the Community Mediator Training Program, visit http://mediation-omc.org/or call 248-338-4280, ext. 227.

###

Share article on social media or email:

EVŌQ Bio is Fielding Partnership Inquiries for its Antimicrobial Medical Materials Additives at the MedTech Conference 2022 in Boston, MA.


EVŌQ Bio (an EVŌQ Nano company), a nano-platform technology company, is pleased to announce their attendance at the MedTech Conference 2022 in Boston, Massachusetts October 24-26, 2022. The MedTech Conference is the premiere venue for executives from across the medical device and technology industry to share the latest advancements and create partnerships. EVŌQ Bio has developed EVQ-218, a nanotherapeutic that shows broad spectrum activity against fungi, gram-negative and gram-positive bacteria without developing drug resistance. In vitro testing at Seattle Children’s Research Institute and animal studies at Lovelace Biomedical has confirmed efficacy against 60+ strains of multi-drug resistant bacteria while exhibited no toxicity at therapeutic doses. Third party minimum inhibitory concentration and biofilm inhibitory concentration testing demonstrated comparable or improved outcomes against leading antibiotics. EVŌQ Bio will be using this opportunity to take meetings on the many uses of EVQ-218 as an antimicrobial additive to a variety of potential applications. “Infections related to surgical and medical devices continue to rise, demanding new solutions,” said David Nilson, Vice President of EVŌQ Bio. “Our novel technology has been shown to radically reduce the onset of bacteria colonization and biofilm formation on inserted and implanted devices, thus decreasing the number of nosocomial infections. The broad-spectrum activity of our technology shows efficacy against staph, E. coli, pseudomonas, burkholderia and all NTM strains tested.” In addition to medical devices, EVŌQ Bio’s poly-therapeutic platform leverages nano-technology in the development of antimicrobial applications, including a pulmonary therapeutic to treat bacterial lung disease. EVŌQ Bio’s attendance at Medtech seeks to develop partnerships to bring this technology to multiple device and supply manufacturers. EVŌQ Bio will be fielding meeting requests throughout the event via in-person requests and the Medtech Partnering Platform. About EVŌQ Bio EVŌQ Bio (an EVŌQ Nano, Inc company) is a nano-technology platform company developing early-stage pharmaceutical research and medical device applications to reduce the global threat of multi-drug resistant infections. Our technology and unique mechanism of action enables treatment and prevention of bacterial disease, without contributing to the growing list of drug-resistant pathogens.

Share article on social media or email:

Confusing Standards of Identity and Imitation Milk Labeling


News Image

Less than 7% of respondents associated an imitation label with skim milk without added vitamins. Some vitamins and fats are removed from skim milk in the process of removing milk fat to create the product, and some consumers prefer to purchase food without additives. Requiring skim milk without added vitamins to be labeled as imitation could increase, not decrease, consumer confusion. If the imitation label did not accurately communicate product contents, then the standard of identity is not actually protecting consumers.

In the new article released in the open access Journal of the Agricultural & Applied Economics Association, “Standards of identity and Imitation Milk Labeling“, Brandon McFadden from the University of Arkansas asks if it is possible that standards of milk labeling can increase consumer confusion instead of reducing it.

McFadden says, “We need to be more thoughtful about standards of identity. Allowing firms to meet the desires of specific consumer segments while also protecting consumers from misleading claims and marketing campaigns can be a fine line to toe. If the goal of standards of identity is to provide accurate information about product contents to consumers, then research is needed to better understand how labels and claims are perceived by consumers. Too stringent standards of identity can simultaneously harm firms and increase consumer confusion.”

If you are interested in setting up an interview, please contact Allison Ware in the AAEA Business Office.

ABOUT AAEA: Established in 1910, the Agricultural & Applied Economics Association (AAEA) is the leading professional association for agricultural and applied economists, with 2,500 members in more than 60 countries. Members of the AAEA work in academic or government institutions as well as in industry and not-for-profit organizations, and engage in a variety of research, teaching, and outreach activities in the areas of agriculture, the environment, food, health, and international development. The AAEA publishes three journals, the Journal of the Agricultural and Applied Economics Association (an open access journal), the American Journal of Agricultural Economics and Applied Economic Perspectives & Policy, as well as the online magazine Choices and the online open access publication series Applied Economics Teaching Resources. To learn more, visit http://www.aaea.org.

Share article on social media or email:

Broward Guardian, Memorial Healthcare System’s Accountable Care Organization, Ranked #1 in the U.S. for Shared Savings Per Beneficiary Among Healthcare System-owned ACOs


Broward Guardian is an accountable care organization operated by Memorial Healthcare System.

“These results were accomplished through the enhanced coordination of care among a network of primary care and specialty physicians supported by professionals and technology housed in Memorial’s value-based care division.” – Matthew Muhart, Memorial Healthcare System Chief Strategy Officer

Recently, the Center for Medicare and Medicaid Services (CMS) released the results of all ACO’s performance in the Medicare Shared Savings Program (MSSP). In this latest reconciliation for the performance year 2021, Broward Guardian ACO, which was purchased by Memorial Healthcare System (“Memorial”) in May of 2020, had the highest savings per beneficiary of any other high revenue (or health-system-owned) ACO in the nation in the MSSP program.

Broward Guardian has achieved a cumulative $36 million in shared savings since its inception in 2014 while caring for close to 9,000 beneficiaries. For the most recent program year of 2021, Broward Guardian achieved more than $11 million in savings in the program of which they received more than $8 million.

“These results were accomplished through the enhanced coordination of care among a vibrant and dedicated community-wide network of primary care and specialty physicians supported by a very robust team of professionals and technology resources housed in Memorial’s value-based care division,” said Matthew Muhart, Memorial’s Executive Vice President and Chief Strategy Officer. “Working together, we provide not only the chronic condition management many Medicare beneficiaries need, but the sorely needed navigation to care and other services, such as support for socioeconomic needs, which are often barriers to accessing care, and are necessary for keeping a population healthy.”

Since the purchase in 2020, Memorial has invested in technology, infrastructure, analytics, and numerous clinical resources for Broward Guardian to improve the health of the populations in the communities they serve and to reduce the total cost of care by helping patients receive the right care at the right time and in the right setting.

“The deployment of these resources across all of our value-based care programs including Broward Guardian, Memorial Health Network – our commercial ACO managing approximately 200,000 members – participation in approximately 20 bundle payment programs under Medicare’s BPCI-A program, and our co-branded Medicare Advantage Health Plan with Holy Cross Health and Oscar are producing incredible results, improving people’s health, and making the cost of healthcare more efficient,” said Monica Puga, Sr. VP, and Chief Nursing Executive.

There are close to 800 primary and specialty providers in the Broward Guardian ACO, providers that have partnered with Memorial on this value-based care journey. At the top level, Memorial is committed to care transformation, technology enablement, and innovation to support growth in the ACO.

Broward Guardian ACO performance depends on the innovative, technology-based clinical support and the collaboration among physicians, specialists, and clinical operations which collectively have resulted in optimized clinical, quality and financial outcomes.

“It is clear to us that our stakeholders; our patients and their families, the employers in our community, our physicians, and our commercial and governmental payers are expecting more from us, which means improving the health of our community and becoming more cost-efficient. These results validate Memorial is leading the way in South Florida,” Muhart said.

                                                                                 # # #

About Broward Guardian:

Acquired by Memorial Healthcare System in 2020, Broward Guardian was first formed in 2013 as a primary care-focused organization and began as a Track 1 ACO in 2014 in the Medicare Shared Savings Program. Broward Guardian advanced to a Track 3 ACO in the Medicare Shared Savings Program in 2017 and is currently in the Enhanced track. Currently, there are 39 ACO participants and 795 ACO providers and suppliers with approximately 9,000 Medicare beneficiaries attributed to Broward Guardian ACO.

About Memorial Healthcare System:

Memorial Healthcare System is one of the largest public healthcare systems in the U.S. and a national leader in quality care and patient satisfaction. It is highly regarded for a patient and family-centered approach at facilities that include Memorial Regional Hospital, Joe DiMaggio Children’s Hospital, Memorial Regional Hospital South, Memorial Hospital West, Memorial Hospital Miramar, Memorial Hospital Pembroke, Joe DiMaggio Children’s Health Specialty Center in Wellington, and Memorial Manor nursing home.

Among the many awards and recognition, it has earned are Modern Healthcare magazine’s “Best Place to Work in Healthcare,” Florida Trend’s “Florida’s Best Companies to Work For,” and Becker’s Hospital Review’s “150 Great Places to Work in Healthcare.” In a recent report (“Humanizing Brand Experience”), the Denver-based consulting firm Monigle named Memorial the top health system brand in America, based on consumer surveys.

Share article on social media or email:

Cloud Automation is Speeding Up Innovation in Pharma and Life Sciences


News Image

Researchers and scientists need on-demand access to application services, but compliance concerns mean they are not able to simply go to the public cloud like those in other industries

In recent years, the life sciences and pharma industries have experienced an increase in regulatory oversight while also facing pressure to respond to global healthcare crises. This tension between regulation and innovation will only increase as security and data privacy concerns limit the ability of many industries to take advantage of public cloud services.

Looking forward, as technology expands, these industries will continue to see a steady escalation in regulations. “By optimizing data sharing and advancing collaboration and innovation, cloud computing can facilitate world-changing discoveries.”¹ Herein lies a unique difficulty for those operating within life sciences and pharma industries — organizations must innovate at the fastest pace possible to compete while still adhering to critical regulatory requirements. As the reliance on technology increases, the pace of R&D in pharma and life sciences is becoming bottlenecked by internal IT processes that are historically unable to compete with the speed of service delivery provided by public clouds.

“In highly regulated sectors, there has been a lot of frustration on the part of teams that feel handcuffed by legacy approaches to IT,” Brad Parks, Chief Product and Marketing Officer at Morpheus Data. “Researchers and scientists need on-demand access to application services, but compliance concerns mean they are not able to simply go to the public cloud like those in other industries.”

This is where Morpheus Data provides innovative hybrid cloud management technology that makes it possible for researchers and teams to move faster while still meeting strict regulatory guidelines and process controls. Through a unified orchestration and automation platform, teams get instant on-demand access to the applications they need to advance their research agenda without having to wait on manual IT processes. Individual users can request organizationally approved application services from a simple self-service portal or API, which means they can constantly analyze data sets, iterate, and test again without delay. At the same time, IT and security teams are able to set strict policies around where applications are deployed and how data is accessed. By retaining critical control of organization-wide governance, IT can protect the organization from risk.

With the Morpheus hybrid cloud management platform, organizations can get the speed and efficiency of the public cloud within the safety and security of their on-premises datacenter. The platform integrates with the datacenter tools and hypervisors that organizations already have, reducing the number of manual tasks that must be performed each time an application service is provisioned. This helps those operating in highly regulated environments access the data sets and applications they need to perform testing in minutes rather than waiting days, weeks, or months for IT to provide assistance.

One Morpheus Data client, AstraZeneca, cites that a service delivery process that previously took 80 hours per server end-to-end can now be accomplished in 27 minutes, start to finish. AstraZeneca also found they saved over six-million dollars in IT overhead by automating their hybrid-cloud estate with Morpheus.

In the future, pharma and life sciences organizations that are highly automated will be poised to be able to innovate the fastest. These teams will be able to process patents, receive approvals, and move through the FDA at speed. Automating and orchestrating private cloud environments will allow these teams to operate efficiently while still adhering to strict security and regulation requirements.

To learn more about how Morpheus can help speed up innovation while reducing risk, download the whitepaper Market Insight Report.

About Morpheus Data:

Morpheus Data is the leader in hybrid cloud application orchestration, helping hundreds of organizations in life science, pharmaceutical, financial services, and other industries unleash productivity and address IT operations skills gaps through their unified software platform. The Morpheus platform enables self-service provisioning of VMs, Containers, Clusters, and Application Stacks into any private or public cloud while staying within policy guardrails. For more information and to request a personalized platform demo, visit http://www.morpheusdata.com/demo.

Reference:

1. Team, E. (2020, December 17). Why do biotech and pharma need so much computing power in the cloud? Atlantic.Net. Retrieved October 6, 2022, from https://www.atlantic.net/life-sciences-pharma-biotech/biotech-pharma-need-much-computing-power-cloud/

Share article on social media or email:

Dracen Pharmaceuticals announces publication in Molecular Cancer Therapeutics


Dracen Pharmaceuticals Inc., a clinical stage biotech company developing anti-cancer drugs that target immuno-metabolism, announced today the publication in Molecular Cancer Therapeutics of a scientific peer-reviewed article entitled: “Sirpiglenastat (DRP-104) Induces Anti-tumor Efficacy Through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate & Adaptive Immune Systems” (https://aacrjournals.org/mct/article-abstract/21/10/1561/709527/Sirpiglenastat-DRP-104-Induces-Antitumor-Efficacy?redirectedFrom=fulltext).

“Glutamine metabolism has been considered an important mechanism to control tumor growth and survival. Here, we describe the preclinical pharmacology and mechanisms of action of the novel clinical stage glutamine antagonist, DRP-104 (sirpiglenastat),” said Robert Wild, PhD, Dracen’s chief scientific officer. “By broadly targeting all 10 glutamine-metabolizing enzymes, DRP-104 leads to profound anti-tumor activity related to both direct effects on tumor metabolism as well as immune mediated activity via remodeling of the tumor microenvironment and induction of both innate and adaptive anti-tumor immunity. This unique mechanism of action shows promise treating various tumors including those resistant to IO checkpoint inhibitors. We are excited to continue the clinical development of this differentiated agent both as a monotherapy and in combination with immune checkpoint blockade.”

About DRP-104

Our lead glutamine antagonist, DRP-104 (sirpiglenastat), is currently in clinical development. The mechanisms of action for DRP-104 include a) direct inhibition of tumor cell addiction to glutamine metabolism leading to substantial single agent activity and tumor regression; b) broad metabolic remodeling of the tumor microenvironment leading to enhanced anti-tumor immune activity; and c) stimulation of T effector, NK and NKT cells and inhibition of immunosuppressive MDSC and macrophage cells, leading to greater long-term durable responses and survival.

About Dracen Pharmaceuticals

Dracen Pharmaceuticals, Inc. is a privately held biotech company developing proprietary anti-cancer drugs that target immuno-metabolism. Dracen’s investors include Deerfield Management; i&i Biotech Fund (i&i Bio); Osage University Partners; and The Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague). Dracen has operations in San Diego, CA.

Share article on social media or email:

Prime Care Technologies and Century Rehabilitation Introduce Industry-First Therapy-to-Clinical Discrepancy Tracker; Automates Process to Improve Care and Reimbursement


Today Prime Care Technologies and Century Rehabilitation announce a strategic alliance to deliver better patient outcomes by integrating therapy and clinical electronic health records (EHR) data to senior care providers. Prime Care will use its industry-leading primeVIEW dashboard application to offer these consolidated data analytics to mutual Century Rehabilitation clients.

The partnership’s new therapy capabilities achieve three important goals. First to identify differences in assessment data captured by therapists and clinical staff. Second to present those differences in a near real-time alerts-based tool, to be addressed proactively before a care plan and its associated reimbursement is finalized. Third to reduce reliance on manual and time-consuming analysis of assessment and care data. The result is improved patient care and reimbursement accuracy.

The therapy capabilities also enhance primeVIEW’s existing analytics and dashboard capabilities. Therapy, clinical, and administrative staff can view current statistics and trends for a single facility or as an aggregate of multiple facilities. This helps providers identify opportunities to train employees and improve coordination between therapy, clinical, and reimbursement staff.

Integrating and aggregating data directly from EHRs and other core information systems, primeVIEW offers a single analytics dashboard that transforms the way organizations make decisions. At its core, primeVIEW is data you care about, simplified. One login delivers a multi-dimensional view of single or multi-facility performance, empowering leaders to drive productivity using critical benchmarks, rankings, and trends.

Century Rehabilitation is reinventing the therapy-SNF partnership by delivering therapy margin growth while helping to see patients through the continuum of care. The company provides therapy, recruiting, and consulting services to skilled nursing and outpatient facilities.

Said Steve Hemke, Chief Strategy Officer at Century Rehab, “PDPM is fully implemented across our industry. But facilities simply are not staffed to compare every aspect of therapy’s assessments to those completed by the clinical team. Automating this labor-intensive task is essential to great care and a facility’s financial health.”

Century Rehabilitation’s CEO, Tammy Tuminaro added, “This isn’t just about improving the therapy care. Patient outcomes are dependent on collecting the perspectives of interdisciplinary caregivers. Patient care plans and the associated reimbursement are optimized only when all caregiver perspectives are integrated.”

“Prime Care has deep senior care expertise and the primeVIEW platform already provided robust integration with clinical, staffing, pharma, and other data. It was a natural fit to integrate therapy data and offer our clients a single view of their patients and facilities,” said Helmke.

Said Jonathan Duvall, Senior Director of Product Management at Prime Care, “We understand the pressure nursing homes are under to provide therapy and ensure patients’ progress while also facing a labor shortage.” He continued, ” Identifying and communicating care needs doesn’t have to be a time-consuming review of care plans and MDS data. This integration has the potential to convert two-hour meetings with therapy providers into 15-minute conversations over easy-to-compare assessments. Efficiency through technology is now essential to delivering high-quality care and receiving adequate reimbursement for this care.”

Coordinated interdisciplinary care between skilled nursing and therapy teams is the ultimate measure of success among senior caregivers in today’s market. The Prime Care and Century Rehabilitation alliance empowers providers to efficiently coordinate, track, and deliver exceptional skilled nursing care.

About Prime Care Technologies

For nearly two decades, innovative senior care operators have relied on Prime Care Technologies for the integrated data and technologies they need to make real-time, performance-impacting decisions, within facilities and across communities. Our Atlanta-based operation empowers more than 7,500 facilities to leverage best-in-class technologies. The interoperability we drive across 70+ apps and 3,500+ payers within the senior care market makes Prime Care Technologies the industry-leading data warehouse. The same highly secure IT services we offer clients to support and integrate their most valuable healthcare data are available to all markets as part of our primeCLOUD managed IT services suite. Learn more at http://www.primecaretech.com.

About Century Rehabilitation

Century Rehabilitation provides therapy, recruiting, and consulting services to skilled nursing and outpatient facilities so they can focus on the quality care their patients deserve. Founded on the principles of “doing the right thing” each day for our facilities, patients, and employees, our goal is to be a valued partner and to help improve our clients’ financial, operational, and clinical performance so they can be leaders in compassionate care. Learn more at http://www.centuryrehab.com.

Share article on social media or email:

EPA Approves SRFC Bio’s 24-Hour Residual Sanitizer Product


News Image

“We’re proud of our science team, which was built upon a long history of research to develop this leading-edge and science-backed infection control technology. This product is the next frontier,” said Dr. Bob Godfroid, PhD, president and chief science officer of SRFC Bio, Inc.

DALLAS – Oct. 10, 2022 – SRFC Bio, Inc., a biotechnology company that develops continuously active antimicrobial surface cleaners and coatings, announced today the U.S. Environmental Protection Agency (EPA) registration for a new product based on the company’s third generation antimicrobial technology. The product cleans surfaces, disinfects bacteria and viruses at application, and keeps killing 99.9% of bacteria for up to 24 hours after it dries. Hallmarks of the new product are absence of stickiness and visibility after drying.

“We’re proud of our science team, which was built upon a long history of research to develop this leading-edge and science-backed infection control technology. This product is the next frontier,” said Dr. Bob Godfroid, PhD, president and chief science officer of SRFC Bio, Inc. “Our mission is to help stop the spread of dangerous infections by the transmission of microbes across surfaces. This product will provide healthier environments in the spaces we all live in.”

According to the EPA, areas with surfaces that are frequently touched by many different people can pose a risk to public health because of the significant challenge for continuous cleaning and disinfection. “We are excited to receive EPA registration,” said Dr. Godfroid. “This is a major step for the company in the U.S., and the approval supports further commercialization of our technology platform with our domestic and international partners.”

More information can be found by visiting http://www.srfcbio.com.

# # #

About SRFC Bio, Inc.

SRFC Bio, Inc. is a privately held biotechnology science company based in Dallas, Texas, focused on developing and marketing active antimicrobial surface cleaners and coatings for distribution in the U.S. and worldwide. With a decade of research and more than 100 patents, the company serves global customers in healthcare, hospitality, travel, education, entertainment and many other markets. The team of leading scientists, chemists, microbiologists, and product developers at SRFC Bio, Inc. are committed to creating a future of wellbeing with breakthrough solutions that help eliminate disease transmission. More information can be found at http://www.srfcbio.com.

Editor’s note: Interviews and demonstrations are available upon request with Dr. Bob Godfroid, PhD, president and chief science officer of SRFC Bio, Inc during the ISSA Show North America, Oct. 10-13 in Chicago.

Media Contact

Beth Strautz

(773) 895-5387

beth@vaguspr.com

Chris Reiter

SRFC Bio, Inc.

Chief Commercial Officer

(972) 971-0501

creiter@srfcbio.com

Share article on social media or email:

Deep Bio’s AI Support for Prostate Cancer Diagnosis will be Deployed at Five Korean Hospitals


We are greatly expecting to prove that our software can be seamlessly integrated into the current pathology workflows, bringing positive changes such as reducing pathologists’ work burden and improving efficiency in real clinical settings

Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics software, announced that it will sign trial purchase agreements with five Korean hospitals for its AI-based prostate cancer diagnosis support software, DeepDx®-Prostate Pro, through the Public Procurement Marketplace program run by the Korean Public Procurement Service (PPS). The software was designated as an ‘Innovative Product’ in July 2022.

To successfully complete the integration of DeepDx®-Prostate Pro into the pathology workflows by this November, the hospitals participating in the trial purchase – the SMG-SNU Boramae Medical Center, Chungnam National University Sejong Hospital, Korea Institute of Radiological & Medical Sciences, Jeju National University Hospital, and Gyeongsang National University Changwon Hospital – and Deep Bio are progressing through required procedures and making arrangements. The AI will be used for various purposes, including support for pathologists in tumor severity determination, confirmation of diagnoses, and research.

DeepDx®-Prostate Pro is a deep learning-based medical software that assists the histopathological diagnosis of prostate cancer by analyzing the Whole Slide Image (WSI) of the prostate needle biopsies. It automatically classifies the severity of prostate cancer, which empowers pathologists to make diagnostic decisions with increased accuracy and speed.

“We are greatly expecting to prove that our software can be seamlessly integrated into the current pathology workflows, bringing positive changes such as reducing pathologists’ work burden and improving efficiency in real clinical settings,” mentioned Sun-Woo Kim, CEO of Deep Bio. He also said, “through this trial purchase project, Deep Bio will lead the introduction of digital pathology in Korea as well as accelerate domestic market expansion.”

Korea PPS’ ‘Innovative Product Designation Program’ is a government program that aims to foster the development of innovative technologies. To select Innovative Products, a committee made up of the Korea PPS and experts in each field, such as bio-health, future automobiles, and carbon neutrality, evaluates each registrant based on several criteria including public value and innovation.

Focusing not only on AI diagnostics but also R&D, Deep Bio has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, as well as in various international conferences and events. The company also continues to build its global presence through overseas digital pathology platform providers in the US, Europe, and India, as well as conducting research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US.

About Deep Bio

Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. To learn more, visit http://www.deepbio.co.kr.

DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs (700k+ cores from 2019 to 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability. To learn more, visit http://www.deepbio.co.kr.

Share article on social media or email: